세계의 인공장기 및 메디컬 바이오닉스 시장 : 제품 유형별, 최종 사용자별, 지역별 - 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2032년)

Persistence Market Research, a renowned market research firm, has conducted an in-depth analysis of the global Artificial Vital Organs and Medical Bionics Market. This comprehensive report provides valuable insights into key market dynamics, growth drivers, challenges, and emerging trends. It offers a detailed overview of the artificial vital organs and medical bionics segment within the healthcare industry, presenting exclusive data and statistics projecting the market's growth trajectory from 2024 to 2032.

Key Insights:

• Artificial Vital Organs and Medical Bionics Market Size (2024): USD54.8 Bn
• Projected Market Value (2032): USD107.4 Bn
• Global Market Growth Rate (CAGR 2024 to 2032):8.7%

Artificial Vital Organs and Medical Bionics Market - Report Scope:

The Artificial Vital Organs and Medical Bionics Market encompasses a wide range of artificial organs, bionic devices, and regenerative medicine solutions aimed at replacing or augmenting the function of damaged or failed organs and tissues in patients. This market serves healthcare providers, medical device manufacturers, biotechnology companies, and patients suffering from organ failure, debilitating injuries, or chronic diseases. Artificial vital organs and medical bionics technologies include artificial hearts, bionic limbs, cochlear implants, retinal prostheses, and tissue-engineered organs, among others. Market growth is driven by advancements in biomedical engineering, material science, and regenerative medicine, as well as increasing prevalence of organ failure, trauma injuries, and age-related degenerative disorders.

Market Growth Drivers:

The global Artificial Vital Organs and Medical Bionics Market benefits from several key growth drivers. Technological advancements in prosthetics, implants, and tissue engineering enable the development of more sophisticated and functional artificial organs and bionic devices with improved performance, durability, and biocompatibility. Moreover, increasing demand for organ transplantation alternatives, personalized medicine solutions, and patient-specific implants drives market expansion. Artificial vital organs and medical bionics offer life-saving and life-enhancing options for patients with end-stage organ failure or severe disabilities, improving their quality of life and long-term outcomes. Additionally, supportive regulatory frameworks, government funding initiatives, and public-private partnerships accelerate innovation and market adoption of artificial vital organs and medical bionics technologies.

Market Restraints:

Despite its significant growth prospects, the Artificial Vital Organs and Medical Bionics Market faces challenges related to technology acceptance, cost-effectiveness, and patient access. The high cost of bionic devices, surgical procedures, and postoperative care may limit market penetration and affordability for patients, particularly in low- and middle-income countries with constrained healthcare budgets. Moreover, the complexity and invasiveness of implantation procedures, as well as the risk of complications and device failures, pose challenges for patient acceptance and clinician adoption of artificial vital organs and medical bionics technologies. Furthermore, ethical considerations, social stigma, and cultural attitudes towards human enhancement and augmentation may influence patient and societal acceptance of bionic implants and regenerative medicine therapies. Addressing these barriers requires collaboration between healthcare stakeholders, industry partners, and policymakers to promote access, affordability, and equitable distribution of artificial vital organs and medical bionics technologies.

Market Opportunities:

The Artificial Vital Organs and Medical Bionics Market presents significant growth opportunities driven by technological innovations, patient-centered care models, and market expansion strategies. Emerging trends such as 3D printing, nanotechnology, and bioelectronic medicine offer new avenues for personalized fabrication, miniaturization, and integration of bionic implants and tissue-engineered constructs. The development of biohybrid organs, organoids, and organ-on-a-chip platforms enables more physiological and functional models for drug screening, disease modeling, and personalized therapy development. Moreover, strategic collaborations between academia, industry, and healthcare providers facilitate translational research, clinical trials, and commercialization of artificial vital organs and medical bionics technologies. Furthermore, emphasis on patient education, advocacy, and support services enhances awareness, acceptance, and adherence to bionic implants and regenerative medicine therapies.

Key Questions Answered in the Report:

• What is the CAGR of the Artificial Vital Organs And Medical Bionics Market?
• Which is the Leading Country in the Artificial Vital Organs And Medical Bionics Market?
• Which Segment Leads in the Artificial Vital Organs And Medical Bionics Market by Type?
• What is the Growth Estimated for the Artificial Vital Organs And Medical Bionics Market by 2032?
• Which Region has the highest potential in the Artificial Vital Organs And Medical Bionics Market?

Competitive Intelligence and Business Strategy:

Leading players in the global Artificial Vital Organs and Medical Bionics Market, including medical device manufacturers, biotechnology companies, and academic research institutions, focus on innovation, collaboration, and market expansion to gain a competitive edge. These companies invest in research and development to develop next-generation artificial organs, bionic devices, and regenerative medicine therapies tailored to specific clinical indications and patient populations. Moreover, strategic partnerships with healthcare providers, patient advocacy groups, and regulatory agencies enable companies to validate product efficacy, safety, and market readiness. Furthermore, emphasis on patient-centered design, user experience, and outcomes-based reimbursement models enhances patient satisfaction and healthcare value in the competitive landscape of artificial vital organs and medical bionics.

Key Companies Profiled:

• SynCardia Systems, LLC
• BiVACOR
• CARMAT
• Cleveland Heart
• Jarvik Heart
• MyLVAD
• Thoratec Corporation
• Abbott Diabetes
• Asahi Kasei Medical Co. Ltd.
• Edwards Lifesciences Corporation

Artificial Vital Organs and Medical Bionics Market Research Segmentation:

By Type

• Artificial Vital Organs
• Medical Bionics

By Region

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Market Outlook
• 1.2. Summary of Statistics
• 1.3. Key Market Characteristics & Attributes
• 1.4. Analysis and Recommendations

2. Market Overview

• 2.1. Market Coverage / Taxonomy
• 2.2. Market Definition / Scope / Limitations

3. Market Risks and Trends Assessment

• 3.1. Risk Assessment
  • 3.1.1. COVID-19 Crisis and Impact on Artificial Vital Organs And Medical Bionics Demand
  • 3.1.2. COVID-19 Impact Benchmark with Previous Crisis
  • 3.1.3. Impact on Market Value (US$ Mn)
  • 3.1.4. Assessment by Key Countries
  • 3.1.5. Assessment by Key Market Segments
  • 3.1.6. Action Points and Recommendation for Suppliers
• 3.2. Key Trends Impacting the Market
• 3.3. Formulation and Product Development Trends

4. Market Background and Foundation Data Points

• 4.1. Global Artificial Vital Organs And Medical Bionics Market (US$ Mn)
• 4.2. Artificial Vital Organs And Medical Bionics Market Opportunity Assessment (US$ Mn)
  • 4.2.1. Total Available Market
  • 4.2.2. Serviceable Addressable Market
  • 4.2.3. Serviceable Obtainable Market
• 4.3. Market Scenario Forecast
  • 4.3.1. Demand in optimistic Scenario
  • 4.3.2. Demand in Likely Scenario
  • 4.3.3. Demand in Conservative Scenario
• 4.4. Investment Feasibility Analysis
  • 4.4.1. Investment in Established Markets
    • 4.4.1.1. In Short Term
    • 4.4.1.2. In Long Term
  • 4.4.2. Investment in Emerging Markets
    • 4.4.2.1. In Short Term
    • 4.4.2.2. In Long Term
• 4.5. Forecast Factors - Relevance & Impact
  • 4.5.1. Top Companies Historical Growth
  • 4.5.2. Global Artificial Vital Organs And Medical Bionics Market Growth
  • 4.5.3. Artificial Vital Organs And Medical Bionics Adoption Rate, by Country
• 4.6. Market Dynamics
  • 4.6.1. Market Driving Factors and Impact Assessment
  • 4.6.2. Prominent Market Challenges and Impact Assessment
  • 4.6.3. Artificial Vital Organs And Medical Bionics Market Opportunities
  • 4.6.4. Prominent Trends in the Global Market & Their Impact Assessment

5. Key Success Factors

• 5.1. Manufacturers' Focus on Low Penetration High Growth Markets
• 5.2. Banking on with Segments High Incremental Opportunity
• 5.3. Peer Benchmarking

6. Global Artificial Vital Organs And Medical Bionics Market Demand Analysis 2019-2023 and Forecast, 2024-2032

• 6.1. Historical Market Analysis, 2019-2023
• 6.2. Current and Future Market Projections, 2024-2032
• 6.3. Y-o-Y Growth Trend Analysis

7. Global Artificial Vital Organs And Medical Bionics Market Value Analysis 2019-2023 and Forecast, 2024-2032

• 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
• 7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2032
  • 7.2.1. Y-o-Y Growth Trend Analysis
  • 7.2.2. Absolute $ Opportunity Analysis

8. Global Artificial Vital Organs And Medical Bionics Market Analysis 2019-2023 and Forecast 2024-2032, By Type

• 8.1. Introduction / Key Findings
• 8.2. Historical Market Size (US$ Mn) Analysis By Type, 2019-2023
• 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Type, 2024-2032
  • 8.3.1. Artificial Vital Organs
  • 8.3.2. Medical Bionics
• 8.4. Market Attractiveness Analysis By Type

9. Global Artificial Vital Organs And Medical Bionics Market Analysis 2019-2023 and Forecast 2024-2032, By Region

• 9.1. Introduction
• 9.2. Historical Market Size (US$ Mn) Analysis By Region, 2019-2023
• 9.3. Current Market Size (US$ Mn) & Analysis and Forecast By Region, 2024-2032
  • 9.3.1. North America
  • 9.3.2. Latin America
  • 9.3.3. Europe
  • 9.3.4. Asia Pacific
  • 9.3.5. Middle East and Africa (MEA)
• 9.4. Market Attractiveness Analysis By Region

10. North America Artificial Vital Organs And Medical Bionics Market Analysis 2019-2023 and Forecast 2024-2032

• 10.1. Introduction
• 10.2. Pricing Analysis
• 10.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 10.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2024-2032
  • 10.4.1. By Country
    • 10.4.1.1. U.S.
    • 10.4.1.2. Canada
  • 10.4.2. By Type
• 10.5. Market Attractiveness Analysis
  • 10.5.1. By Country
  • 10.5.2. By Type

11. Latin America Artificial Vital Organs And Medical Bionics Market Analysis 2019-2023 and Forecast 2024-2032

• 11.1. Introduction
• 11.2. Pricing Analysis
• 11.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 11.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2024-2032
  • 11.4.1. By Country
    • 11.4.1.1. Brazil
    • 11.4.1.2. Mexico
    • 11.4.1.3. Rest of Latin America
  • 11.4.2. By Type
• 11.5. Market Attractiveness Analysis
  • 11.5.1. By Country
  • 11.5.2. By Type

12. Europe Artificial Vital Organs And Medical Bionics Market Analysis 2019-2023 and Forecast 2024-2032

• 12.1. Introduction
• 12.2. Pricing Analysis
• 12.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 12.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2024-2032
  • 12.4.1. By Country
    • 12.4.1.1. Germany
    • 12.4.1.2. France
    • 12.4.1.3. U.K.
    • 12.4.1.4. Italy
    • 12.4.1.5. Benelux
    • 12.4.1.6. Nordic Countries
    • 12.4.1.7. Rest of Europe
  • 12.4.2. By Type
• 12.5. Market Attractiveness Analysis
  • 12.5.1. By Country
  • 12.5.2. By Type

13. Asia Pacific Artificial Vital Organs And Medical Bionics Market Analysis 2019-2023 and Forecast 2024-2032

• 13.1. Introduction
• 13.2. Pricing Analysis
• 13.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 13.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2024-2032
  • 13.4.1. By Country
    • 13.4.1.1. China
    • 13.4.1.2. Japan
    • 13.4.1.3. South Korea
    • 13.4.1.4. Rest of Asia Pacific
  • 13.4.2. By Type
• 13.5. Market Attractiveness Analysis
  • 13.5.1. By Country
  • 13.5.2. By Type

14. Middle East and Africa Artificial Vital Organs And Medical Bionics Market Analysis 2019-2023 and Forecast 2024-2032

• 14.1. Introduction
• 14.2. Pricing Analysis
• 14.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 14.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2024-2032
  • 14.4.1. By Country
    • 14.4.1.1. GCC Countries
    • 14.4.1.2. South Africa
    • 14.4.1.3. Turkey
    • 14.4.1.4. Rest of Middle East and Africa
  • 14.4.2. By Type
• 14.5. Market Attractiveness Analysis
  • 14.5.1. By Country
  • 14.5.2. By Type

15. Key Countries Artificial Vital Organs And Medical Bionics Market Analysis 2019-2023 and Forecast 2024-2032

• 15.1. Introduction
  • 15.1.1. Market Value Proportion Analysis, By Key Countries
  • 15.1.2. Global Vs. Country Growth Comparison
• 15.2. US Artificial Vital Organs And Medical Bionics Market Analysis
  • 15.2.1. Value Proportion Analysis by Market Taxonomy
  • 15.2.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
    • 15.2.2.1. By Type
• 15.3. Canada Artificial Vital Organs And Medical Bionics Market Analysis
  • 15.3.1. Value Proportion Analysis by Market Taxonomy
  • 15.3.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
    • 15.3.2.1. By Type
• 15.4. Mexico Artificial Vital Organs And Medical Bionics Market Analysis
  • 15.4.1. Value Proportion Analysis by Market Taxonomy
  • 15.4.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
    • 15.4.2.1. By Type
• 15.5. Brazil Artificial Vital Organs And Medical Bionics Market Analysis
  • 15.5.1. Value Proportion Analysis by Market Taxonomy
  • 15.5.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
    • 15.5.2.1. By Type
• 15.6. Germany Artificial Vital Organs And Medical Bionics Market Analysis
  • 15.6.1. Value Proportion Analysis by Market Taxonomy
  • 15.6.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
    • 15.6.2.1. By Type
• 15.7. France Artificial Vital Organs And Medical Bionics Market Analysis
  • 15.7.1. Value Proportion Analysis by Market Taxonomy
  • 15.7.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
    • 15.7.2.1. By Type
• 15.8. Italy Artificial Vital Organs And Medical Bionics Market Analysis
  • 15.8.1. Value Proportion Analysis by Market Taxonomy
  • 15.8.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
    • 15.8.2.1. By Type
• 15.9. BENELUX Artificial Vital Organs And Medical Bionics Market Analysis
  • 15.9.1. Value Proportion Analysis by Market Taxonomy
  • 15.9.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
    • 15.9.2.1. By Type
• 15.10. UK Artificial Vital Organs And Medical Bionics Market Analysis
  • 15.10.1. Value Proportion Analysis by Market Taxonomy
  • 15.10.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
    • 15.10.2.1. By Type
• 15.11. Nordic Countries Artificial Vital Organs And Medical Bionics Market Analysis
  • 15.11.1. Value Proportion Analysis by Market Taxonomy
  • 15.11.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
    • 15.11.2.1. By Type
• 15.12. China Artificial Vital Organs And Medical Bionics Market Analysis
  • 15.12.1. Value Proportion Analysis by Market Taxonomy
  • 15.12.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
    • 15.12.2.1. By Type
• 15.13. Japan Artificial Vital Organs And Medical Bionics Market Analysis
  • 15.13.1. Value Proportion Analysis by Market Taxonomy
  • 15.13.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
    • 15.13.2.1. By Type
• 15.14. South Korea Artificial Vital Organs And Medical Bionics Market Analysis
  • 15.14.1. Value Proportion Analysis by Market Taxonomy
  • 15.14.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
    • 15.14.2.1. By Type
• 15.15. GCC Countries Artificial Vital Organs And Medical Bionics Market Analysis
  • 15.15.1. Value Proportion Analysis by Market Taxonomy
  • 15.15.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
    • 15.15.2.1. By Type
• 15.16. South Africa Artificial Vital Organs And Medical Bionics Market Analysis
  • 15.16.1. Value Proportion Analysis by Market Taxonomy
  • 15.16.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
    • 15.16.2.1. By Type
• 15.17. Turkey Artificial Vital Organs And Medical Bionics Market Analysis
  • 15.17.1. Value Proportion Analysis by Market Taxonomy
  • 15.17.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
    • 15.17.2.1. By Type
  • 15.17.3. Competition Landscape and Player Concentration in the Country

16. Market Structure Analysis

• 16.1. Market Analysis by Tier of Companies
• 16.2. Market Concentration
• 16.3. Market Share Analysis of Top Players
• 16.4. Market Presence Analysis
  • 16.4.1. By Regional footprint of Players
  • 16.4.2. Product footprint by Players

17. Competition Analysis

• 17.1. Competition Dashboard
• 17.2. Competition Benchmarking
• 17.3. Competition Deep Dive
  • 17.3.1. SynCardia Systems, LLC
    • 17.3.1.1. Overview
    • 17.3.1.2. Product Portfolio
    • 17.3.1.3. Sales Footprint
    • 17.3.1.4. Strategy Overview
  • 17.3.2. BiVACOR
    • 17.3.2.1. Overview
    • 17.3.2.2. Product Portfolio
    • 17.3.2.3. Sales Footprint
    • 17.3.2.4. Strategy Overview
  • 17.3.3. CARMAT
    • 17.3.3.1. Overview
    • 17.3.3.2. Product Portfolio
    • 17.3.3.3. Sales Footprint
    • 17.3.3.4. Strategy Overview
  • 17.3.4. Cleveland Heart
    • 17.3.4.1. Overview
    • 17.3.4.2. Product Portfolio
    • 17.3.4.3. Sales Footprint
    • 17.3.4.4. Strategy Overview
  • 17.3.5. Jarvik Heart
    • 17.3.5.1. Overview
    • 17.3.5.2. Product Portfolio
    • 17.3.5.3. Sales Footprint
    • 17.3.5.4. Strategy Overview
  • 17.3.6. MyLVAD
    • 17.3.6.1. Overview
    • 17.3.6.2. Product Portfolio
    • 17.3.6.3. Sales Footprint
    • 17.3.6.4. Strategy Overview
  • 17.3.7. Thoratec Corporation
    • 17.3.7.1. Overview
    • 17.3.7.2. Product Portfolio
    • 17.3.7.3. Sales Footprint
    • 17.3.7.4. Strategy Overview
  • 17.3.8. Abbott Diabetes
    • 17.3.8.1. Overview
    • 17.3.8.2. Product Portfolio
    • 17.3.8.3. Sales Footprint
    • 17.3.8.4. Strategy Overview
  • 17.3.9. Asahi Kasei Medical Co. Ltd.
    • 17.3.9.1. Overview
    • 17.3.9.2. Product Portfolio
    • 17.3.9.3. Sales Footprint
    • 17.3.9.4. Strategy Overview
  • 17.3.10. Edwards Lifesciences Corporation
    • 17.3.10.1. Overview
    • 17.3.10.2. Product Portfolio
    • 17.3.10.3. Sales Footprint
    • 17.3.10.4. Strategy Overview

18. Assumptions and Acronyms Used

19. Research Methodology